Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Lexeo Therapeutics, maintaining a price target of $23.
October 25, 2024 | 7:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Lexeo Therapeutics, maintaining a price target of $23.
The reaffirmation of a Buy rating and a specific price target by Chardan Capital is likely to positively influence investor sentiment and potentially drive the stock price up in the short term. The $23 price target suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100